About us

To enhance the quality of life.

Committed to developing and exploring breakthrough therapies to fulfill our promise to patients, employees, and society.

Relying on the world's leading MSC stress induction technology with its own intellectual property rights, the company has induced the screening of multifunctional proteins and solved the global drug development problems caused by the diversification of triggering factors of neurological disorders, unclear target points, and poor efficacy of single target points.

company overview

Advancing the frontier of
‍stress-induced stem cell technologies
to reshape regenerative medicine
and unlock transformative solutions
for previously unmet medical needs.

Founded in 2016, we at Beijing Darwin Cell Biotechnology Co., Ltd. are a national high-tech enterprise and a recognized “Specialized, Refined, Distinctive, and Innovative” SME in Beijing. We are proud to be the first biopharmaceutical company to lead the Sci-Tech Innovation Consortium organized by the Beijing Association for Science and Technology, and we are also one of the founding entities of the Beijing Neurorepair Industry Innovation Center. Together with Beijing Tiantan Hospital, Capital Medical University (the National Center for Neurological Disorders), we have co-established a joint translational laboratory focused on ALS and neurorepair technologies.

Our core expertise lies in stem cells, exosomes, and protein polymer technologies. We are committed to tackling some of the most pressing medical challenges of our time—namely, neurorepair, articular cartilage regeneration, and organ restoration.

We operate three GMP-standard laboratories: a central R&D lab, a clinical lab, and a pilot-scale process development lab. Among our three wholly owned subsidiaries, two specialize in biopharmaceuticals and biomedical consumables, while the third is a manufacturing entity equipped with a fully integrated GMP-compliant freeze-drying production line, handling consumables manufacturing.

Our first independently developed Class I biological drug, Aleeto (DEW001), is designed to treat central nervous system (CNS) diseases such as ALS (amyotrophic lateral sclerosis), stroke, and Alzheimer’s disease, all of which currently lack effective therapies. In 2023, a double-blind IIT clinical study led by the National Center for Neurological Disorders (Beijing Tiantan Hospital) showed that Aleeto significantly slowed motor function decline in ALS patients—with some even experiencing reversal of neurological dysfunction—and demonstrated an excellent safety profile. In preclinical studies for stroke, Aleeto was shown to cross the blood-brain barrier and selectively repair damaged neurons, reducing the incidence of long-term complications by more than 70%. Tiantan Hospital is currently conducting an IIT clinical trial to further validate these results.

As the world’s first innovative drug derived from stem cell–extracted protein polymers, Aleeto (DEW001) has successfully completed industrial-scale transformation. Our foundational and clinical research confirms that Aleeto breaks through the boundaries of conventional drug development, pioneering an entirely new therapeutic direction. Once approved, Aleeto will fill the unmet clinical needs in major CNS diseases and may become the first drug capable of reversing neurological dysfunction.

We are proud of what we’ve achieved—and even more excited about what lies ahead.

milestons

Two Decades of Innovation in Neuro Repair Development

Founding and Initial Development (2016 - 2021)

The company was founded in Beijing in 2016. In the initial years, it focused on establishing clinical centers and research platforms. In 2017, it set up the Mayo Yihe Clinic and Zijing Medical Management Consulting Co., Ltd. The following year, it completed the process development for Aleeto®. In 2019, it administered Aleeto® to the first neurological repair patient under compassionate use and established a second laboratory at the Second Affiliated Hospital of Tsinghua University. From 2020 to 2021, it made progress in clinical studies related to COVID-19, established a protein polymer research platform based on Aleeto®, and registered new monoclonal and consortium strains under the name “Darwin Biotech.” It also founded three subsidiaries.

Expansion and Deepening Research (2022 - 2023)

In 2022, the company was recognized as a National High-Tech Enterprise, established Darwin Nuogao (Beijing) Biotechnology Co., Ltd., and initiated clinical trials for recombinant collagen scaffold materials. In 2023, it completed corporate restructuring into two business segments: Serious/Clinical Medicine and Consumer Healthcare. It also launched the ALS clinical program for Aleeto® and initiated key national R&D projects related to Aleeto®. The company received preliminary approval for the Beijing Center for Innovation in Neural Repair Industry and led the establishment of the Beijing Neural Repair Industry Collaborative Alliance.

Transformation and Diversified Collaboration (2024)

In 2024, the company co-founded the Joint Laboratory for ALS and Neural Repair with Beijing Tiantan Hospital, Capital Medical University. It launched the “Wings of Wind” Special Charity Fund and initiated clinical studies on Alzheimer’s disease. The company also collaborated with multiple institutions, including Peking University Basic Medical Sciences, Fudan University, and Bozhen Biotech, to conduct studies on various aspects related to Aleeto® and neurological conditions.

oUR TEAM

Clinical Research, Scientific Innovation, and Biopharmaceutical Development

Our team consists of experienced scientists and industry experts with an average of over 20 years in drug development and neurobiology. With diverse backgrounds in cell biology, molecular genetics, and regenerative medicine, we specialize in tackling neurodegenerative diseases. Driven by innovation and a commitment to excellence, we integrate rigorous science with clinical application to deliver cutting-edge solutions in cell biotechnology, advancing human health and driving industry progress.